50
Participants
Start Date
February 15, 2021
Primary Completion Date
March 14, 2024
Study Completion Date
March 31, 2025
Iohexol
Iohexol (Omnipaque; GE Healthcare, Milwaukee, WI) is a low-osmolar non-ionic iodinated contrast agent that is approved by the FDA for oral use. It is routinely used orally for CT scans of the abdomen and pelvis, and has been used experimentally in CTC. Iohexol is better tolerated by patients and has a better safety profile than hyperosmolar iodinated and barium based contrast agents.
Montefiore Medical Center, The Bronx
Collaborators (1)
GE Healthcare
INDUSTRY
Montefiore Medical Center
OTHER